E-tegra™
STENT GRAFT SYSTEM
Every Day. Every Case.
Product Overview
1. POSITIONING
Separate release of the proximal stent is designed to provide precise placement of the stent graft.
2. FIXATION
Proximal laser cut stent with hooks for suprarenal stent graft fixation.
3. SEALING
Special stent design for improved proximal sealing.
4. FLEXIBILITY
Asymmetrical springs designed for 360 degree flexibility.
5. PATENCY
Oval-shaped bifurcation spring sewn at the inner surface for improved flow and opening ratio.
6. CONFORMABILITY
Asymmetric stent design and seamless cover enable adaptation to the vessel.
7. COMPATIBILITY
Designed for E-liac extension.
1. TIP CAPTURE MECHANISM
2. ACCESSIBILITY
The hydrophilic coating eases introduction and advancement of the system.
3. FLEXIBILITY
The catheter enables safe pushability and precise trackability.
4. PRECISION
The Squeeze-to-Release mechanism allows for gradual or continuous release with minimum effort.
5. ADAPTABILITY
User-friendly delivery system for all leg extensions.
6. CONTROL
The control handle secures the position of the delivery system during the procedure.
7. SAFETY
Release button remains securely locked until proximal stent release is activated.
E-tegra is easy to handle, with smart engineeing and it seems to be a mature stent graft, able to compete with the dominant players in the field.
Clinical Evidence
Main Outcomes from Latest Publications
EASY Study1 (N=151)
E-tegra™ has been specifically designed for improved proximal sealing, flexibility and patency; with 98% technical success, 100% limb patency and ≤ 0.8% endoleak type Ia at follow-up.
TIGRE Registry2 (N=147)
E-tegra™ is Safe And Effective In Treating AAAs with Standard And Hostile Anatomy.
The mid-term outcomes of the Registry confirm optimal safety and effectiveness of the E-tegra™ endograft in treating AAAs with hostile and standard anatomy. Univariate and multivariate analyses showed no significant differences in terms of complications or reinterventions based on hostile anatomy levels.
E-tegra™ & E-liac™
One Solution for your
Aorto Iliac Needs.
Additional Resources
Explore additional resources for E-tegra below. For further information or to contact a sales associate in your area, contact us.
Product Overview:
-
Brunkwall et al., Prospective study of the E-liac Stent Graft System in patients with common iliac artery aneurysms: 30-Day results. Vascular. 2018 Dec;26(6):647-656.
Clinical Evidence
-
- The E-Tegra Device (Artivion) For Infrarenal AAA Treatment: Advantages, Limitations And Results – VEITH Symposium, 2025, New York.
137 patients 12 month FU and 75 patients 24 months FU. - Marone EM, Rinaldi LF, Brioschi C, Bracale UM, Modugno P, Maione M, et al.; Tigre Registry Group. Updates of the TIGRE Registry: anatomic hostility does
not affect mid-term outcomes of endovascular aortic repair with the E-Tegra endograft. Ital J Vasc Endovasc Surg 2025;32:51-7. DOI: 10.23736/S1824-4777.25.01708-5.
- The E-Tegra Device (Artivion) For Infrarenal AAA Treatment: Advantages, Limitations And Results – VEITH Symposium, 2025, New York.
All products and indications are not available/approved in all markets. All trademarks are owned by Artivion, Inc. or its subsidiaries. On-X Life Technologies, Inc., Jotec GmbH, and Ascyrus Medical GmbH are wholly owned subsidiaries of Artivion, Inc. MWENG0022.001. (2026-06)
 |
JOTEC GmbH, Lotzenäcker 23, 72379 Hechingen, Germany |